If you live with diabetes, you probably feel like you have a second, unofficial job:
checking your blood sugar. Fingersticks, logbooks, alarms, math before meals… it’s a lot.
Continuous glucose monitoring (CGM) is designed to make that job easier, more accurate,
anddare we sayless annoying.

Continuous glucose monitoring (CGM) is a diabetes technology that tracks your glucose
(blood sugar) around the clock using a tiny sensor just under your skin. Instead of a
handful of fingerstick checks each day, a CGM gives you a stream of data: your current
glucose level, where it’s heading, and how fast it’s changing. This helps you make smarter
decisions about food, physical activity, and medications, often with fewer surprises.

In this guide, we’ll break down how CGM works, who it’s for, its benefits and downsides,
and what to expect if you’re thinking about trying it. We’ll also share real-world
experiences at the endbecause what happens outside the brochure is often the most useful
part.

How Continuous Glucose Monitoring Works

A CGM system usually has three main parts that work together like a tiny, high-tech
glucose team:

• Sensor: a small flexible filament inserted just under the skin,
  often on the back of the upper arm or abdomen. It measures glucose levels in the
  fluid between your cells (interstitial fluid), not directly in the blood.
• Transmitter: a small electronic piece that sits on top of the
  sensor and sends the glucose data wirelessly.
• Receiver or smart device: this can be a dedicated handheld
  receiver, a smartphone, a smartwatch, or (for some users) an insulin pump.
  It receives the data and displays your glucose readings, graphs, and alerts.

Depending on the brand, a CGM checks your glucose every 1–5 minutes, creating a detailed
picture of your day and night. Some systems stream glucose numbers automatically to your
phone; others need you to scan the sensor with your reader or phone to get a current
reading.

Real-time vs. “Scan” CGM

You’ll often hear about two main styles of CGM:

• Real-time CGM (rtCGM): sends glucose readings continuously in the
  background and can trigger alerts when your levels go too high or too low. Devices
  like Dexcom G6 and G7 fall into this group.
• Intermittently scanned CGM (isCGM): stores data in the sensor and
  shows it when you scan it with a reader or phone (for example, many FreeStyle Libre
  systems). Newer versions can also send optional alarms.

Both types show trends, arrows (indicating the direction of change), and graphs that
help you see what your glucose has been doing over hours and daysnot just the single
“snapshot” you get from a fingerstick meter.

Key CGM Metric: Time in Range

One of the biggest advantages of CGM is a newer way to look at control called
time in range (TIR). For many adults with diabetes, the standard
target range is roughly 70–180 mg/dL, though your own target should be set with your
care team. Time in range is the percentage of the day you spend inside that target
window.

Instead of focusing only on a three-month average (A1C), TIR shows you how often your
glucose is actually in a safe zone. Even small improvements in time in rangesay, 5%
more of the daycan be clinically meaningful. It’s an intuitive way to see whether
your daily choices and your treatment plan are working.

Types of CGM Systems

Modern CGM options have expanded dramatically. While specific brands and features
change over time, most systems fall into a few categories:

Prescription CGMs

These are the most common. They require a prescription from a healthcare provider and
are typically covered by insurance for people who meet certain criteria (such as using
insulin multiple times daily or having frequent hypoglycemia).

• Dexcom systems: real-time CGMs that send data directly to a phone,
  receiver, or compatible insulin pump. Many versions have customizable alerts and
  integrate into “automated insulin delivery” systems.
• FreeStyle Libre systems: often worn on the upper arm, with sensors
  that last around 14 days. Newer models may offer optional alarms and better
  connectivity with apps and devices.

Over-the-counter / Non-insulin CGMs

A newer category of CGMs is aimed at people who are not using insulin or are at lower
risk of dangerous lows, including many people with type 2 diabetes or prediabetes.
Some of these can be bought with fewer barriers, or even without a traditional
prescription, depending on the device and regulations.

These systems are often geared toward understanding how food, movement, sleep, and
stress affect glucose patterns, rather than day-to-day insulin dosing. They may have
fewer alerts but lots of data visualization and coaching features in the app.

CGM Integrated with Insulin Pumps

For people with type 1 diabetes or insulin-dependent type 2 diabetes, some CGMs can
“talk” to insulin pumps. In these systems, the CGM data helps the pump adjust basal
insulin automatically and sometimes give correction doses. This is often called
hybrid closed-loop or automated insulin delivery (AID).

While these systems don’t run on autopilot with no user input (you still have to bolus
for meals and confirm some actions), they can dramatically reduce the mental load of
diabetes management and improve time in range.

Who Can Benefit from CGM?

Some guidelines suggest that almost anyone living with diabetes could potentially
benefit from CGM, but it’s especially helpful for certain groups:

• People with type 1 diabetes: CGM is now considered a standard part
  of care for most people with type 1 who are willing and able to use it. It helps
  with hypoglycemia prevention, overnight monitoring, and fine-tuning insulin.
• People with type 2 diabetes using insulin: If you use multiple daily
  injections or a pump, CGM can highlight patterns after meals, overnight, or with
  exercise that fingersticks may miss.
• People with problematic lows (hypoglycemia): Those with hypoglycemia
  unawareness, frequent nighttime lows, or a history of severe lows may benefit
  significantly from CGM alarms and trend data.
• Children and teens with diabetesand their caregivers: CGM can offer
  peace of mind to parents and help kids stay safer at school, during sports, and
  overnight.
• Pregnant people with diabetes: In many places, CGM is increasingly
  recommended to help keep glucose in a tighter range during pregnancy for the health
  of both parent and baby.

That said, CGM isn’t for everyone. Some people simply don’t like wearing a device on
their body, don’t want the constant stream of data, or find the alerts stressful. Your
preferences matter just as much as the technology.

Benefits of Continuous Glucose Monitoring

So why are CGMs becoming such a big deal in diabetes care? Research and real-world
experience point to several key advantages:

• Fewer fingersticks: Most modern CGMs drastically reduce or even
  eliminate routine fingerstick checks for day-to-day dosing decisions (though you may
  still need a meter if readings don’t match how you feel).
• Better view of patterns: Instead of just seeing “What is my sugar
  right now?”, you can see “What did it do all night?”, “What happens after this
  snack?”, or “What does stress do to my numbers?”
• Time in range improvement: Many people see higher time in range and
  lower A1C after switching to CGM, especially when they review the data with a
  diabetes educator or clinician.
• Hypoglycemia prevention: Low-glucose alerts can help you treat a
  drop before it gets severe. This is especially important at night or if you don’t
  feel your lows.
• Feedback on lifestyle choices: Wonder what that “healthy” smoothie
  is really doing to your glucose? CGM will tell you. You’ll quickly see which foods,
  portion sizes, and timing work better for your body.
• Emotional reassurance (sometimes): For many, seeing the data and
  having alarms provides peace of mindespecially for parents of children with
  diabetes.

One of the underrated benefits is the ability to experiment. You can test small changes
like eating earlier, adding a short walk after dinner, or adjusting a basal rateand
see the impact in real time. It turns your body into a science project, but in a
good way.

Limitations, Risks, and Recent Safety Concerns

As powerful as CGM is, it does come with downsides and important cautions.

Accuracy and “Lag Time”

CGMs measure glucose in interstitial fluid, which lags a bit behind your blood. During
rapid changeslike after you correct a low or sprint up the stairsthe CGM may trail
your true blood glucose by several minutes. This is expected, but it can be confusing.

For this reason, device instructions usually say that if your CGM reading doesn’t match
your symptoms, you should confirm with a fingerstick meter before making a major
treatment decision.

Skin Issues and Adhesives

Some people develop skin irritation, redness, or allergic reactions to the sensor
adhesive. Rotating sites, using barrier sprays or patches, and working with a
dermatologist or diabetes care team can help, but for a small number of users this can
be a dealbreaker.

Cost and Insurance Coverage

CGMs can be expensive, especially without insurance coverage. Even with coverage, there
might be copays, deductibles, or limits on how many sensors you can get. Coverage rules
vary by insurer and country, and they are changing quickly as CGM becomes more
mainstream.

Alert Fatigue and Data Overload

While alerts can be lifesaving, too many alarmsespecially at nightcan lead to
“alert fatigue,” where people start ignoring or disabling them. Likewise, some users
feel overwhelmed by constant data. Working with your care team to set sensible alert
thresholds and reviewing data periodically (instead of obsessively) can help.

Device Problems and Recalls

Like any medical technology, CGM systems occasionally face technical issues, including
sensor failures, connectivity problems, or, rarely, batches that give inaccurate
readings. Recently, some CGM sensors from specific lines have been corrected or
replaced due to risk of falsely low readings. Manufacturers and regulators monitor
these issues closely, but it’s important to pay attention to official notices.

If your CGM readings ever seem suspicious or don’t match how you feel, rely on a blood
glucose meter and contact your healthcare team or the device manufacturer for guidance.

Getting Started with CGM: What to Expect

Curious about trying CGM? Here’s what the process often looks like.

1. Talk with Your Healthcare Provider

Start by discussing CGM with your diabetes care team. They’ll consider factors like:

• Your type of diabetes and current therapy
• How often you experience high or low blood sugar
• Your comfort with technology
• Insurance coverage and device availability in your area

Together, you can choose a device that fits your lifestylewhether that means strong
alerts, tighter integration with a pump, or something simpler.

2. Training and Insertion

When you start CGM, you’ll either meet with a diabetes educator, nurse, or device
trainer in-person or virtually. They’ll show you:

• How to insert the sensor using the applicator
• Where on your body you can place it
• How to attach the transmitter, if separate
• How to pair the sensor with your phone, receiver, or pump

The insertion process is typically quick and feels like a brief pinch or pressure.
Many people are surprised by how easy it is after the first try.

3. Learning the App and Reading the Graphs

The app or receiver will show:

• Your current glucose number
• Trend arrows (rising, falling, stable)
• Graphs showing hours or days of data
• Stats like time in range, average glucose, and variability

Early on, it’s helpful to review your graphs with a professional. They can help you
interpret the patterns and suggest specific changessuch as adjusting insulin dosing
timing, changing meal composition, or planning snacks differently.

4. Building CGM into Your Routine

Over time, you’ll develop your own rhythm:

• Changing sensors every 7–14 days, depending on the model
• Charging or replacing transmitters as needed
• Deciding which alerts to keep on and at what thresholds
• Downloading or sharing data with your care team before appointments

The goal isn’t perfection. It’s better information, fewer surprises, and a little less
mental stress around diabetes decisions.

Everyday Experiences with CGM: What People Often Report

Beyond the technical specs and clinical studies, what does CGM actually feel like in
everyday life? While everyone’s journey is different, many people share similar themes.
The following examples are composites based on common experiences.

1. “I finally see the patterns I always suspected.”
Alex, a 35-year-old with type 1 diabetes, thought mornings were his problem. His
fingerstick checks before breakfast were often high, so he assumed his overnight
insulin was too low. After starting CGM, he realized he was actually dropping very low
around 3 a.m., rebounding by morning. The fix wasn’t “more insulin”it was adjusting
his overnight basal and having a small, earlier snack. Without CGM’s overnight graph,
that pattern might have stayed hidden.

2. “Food experiments became less of a mystery.”
Carmen, living with type 2 diabetes and using insulin, used to dread restaurant meals.
With CGM, she began testing small changes: taking a short walk after pasta, swapping
soda for water, or ordering half portions. She could see the impact on her time in
range after each meal. Some “healthy” choices (like a huge fruit smoothie) turned out
to spike her glucose far more than expected, while a balanced plate with protein,
vegetables, and a small dessert fit much better into her day.

3. “My family sleeps better at night.”
For parents of children with diabetes, nighttime can be nerve-racking. One parent
described CGM as “having a baby monitor for glucose.” Sharing data to a phone meant
they could see their child’s numbers from another roomor even another building at a
sleepover or school event. Low-glucose alerts didn’t remove all the worry, but they
made nighttime less of a guessing game.

4. “The alerts were overwhelming at first.”
Not all feedback is glowing. Some users describe the first weeks with CGM as “alarm city.”
High alerts went off after every pizza slice; low alerts chirped after a tough workout;
their phone suddenly felt like a nagging coach. The turning point usually comes when
people customize alert thresholds and learn when to act versus when to simply observe
a trend. With support, many move from feeling judged by the numbers to feeling informed
by them.

5. “It’s helpfulbut it’s not magic.”
A common realization is that CGM doesn’t “fix” diabetes by itself. It doesn’t dose
insulin for you (unless it’s connected to an automated system), and it can’t force you
to change habits. What it does offer is informationsometimes uncomfortable information
that can guide better decisions over time. People who benefit most are usually those
who are willing to look at the data, learn from it, and collaborate with their care
team.

6. “My relationship with numbers changed.”
For some people, seeing every single rise and fall can increase anxiety at first.
Others find it empowering: instead of mysterious highs “out of nowhere,” they see
specific triggersstressful meetings, skipped snacks, or certain foods. With support,
many users learn to treat CGM data as neutral information rather than a grade on how
“good” or “bad” they’re doing.

Overall, real-world experiences show that CGM can bring both freedom and responsibility.
Most long-term users say they would not want to go back to life without it, but they
also emphasize the importance of good training, realistic expectations, and occasional
digital detox from obsessing over every reading.

Bottom Line

Continuous glucose monitoring (CGM) is more than just a gadgetit’s a powerful tool
that can transform how you understand and manage diabetes. By tracking your glucose
around the clock, CGM helps reveal hidden patterns, improve time in range, and reduce
the burden of constant guesswork.

CGM isn’t perfect. It comes with costs, learning curves, and occasional technical
hiccups. But for many people, the benefitsfewer surprises, more informed choices, and
better long-term controlare well worth it.

If you’re curious about CGM, the best next step is simple: talk with your healthcare
provider or diabetes educator. Bring your questions, your concerns, and maybe a bit of
healthy curiosity. With the right device, training, and support, CGM can become one of
the most useful tools in your diabetes toolbox.

The post What Is Continuous Glucose Monitoring (CGM)? appeared first on Best Gear Reviews.

If you live with diabetes (or love someone who does), you already know the “treatment plan” isn’t just a planit’s a full-time group chat
between your body, your food, your schedule, your stress, and the occasional surprise workout known as “running late.”

In 2023, diabetes care took some genuinely meaningful steps forward. Not in the “we invented a new inspirational poster” way, but in the
“your tech can help prevent dangerous lows,” “your meds can do more than just lower A1C,” and “more people can actually access modern tools” way.
This article breaks down the biggest diabetes treatment advancements of 2023what changed, why it mattered, and how these changes showed up in real life.

Quick safety note: This is educational information, not personal medical advice. Diabetes treatment is highly individualizedalways work with a
qualified clinician for decisions about medications, devices, dosing, and targets.

1) Automated Insulin Delivery Took a Big Leap Forward

Automated insulin delivery (AID) systemsoften called “artificial pancreas” or “closed-loop” systemsare designed to adjust insulin delivery using data from a
continuous glucose monitor (CGM). Think of it as your devices working together so you don’t have to manually “pilot” every glucose bump and dip.

The iLet Bionic Pancreas: a new kind of “set it up, then live” approach

In May 2023, the FDA cleared the Beta Bionics iLet system for people ages 6 and older with type 1 diabetes. What made this newsworthy wasn’t just “another pump.”
It was the system’s emphasis on automation and simplified setupaiming to reduce the mental load of constantly calculating and correcting.

Translation: fewer moments where you feel like you’re taking a pop quiz in carbohydrate math… while you’re also trying to eat, talk, parent, work, or be a human.

MiniMed 780G: meal detection and frequent auto-corrections

In 2023, the FDA also approved Medtronic’s MiniMed 780G system, another AID option that uses CGM trends to automate insulin delivery. One headline feature was
more frequent automatic correction dosinghelpful for real life, where meals don’t always go according to the spreadsheet you never made.

Why this mattered in 2023

The American Diabetes Association (ADA) continued to emphasize diabetes technology in its Standards of Care, reflecting growing evidence that CGM and AID can improve
glucose outcomes and reduce hypoglycemia risk for many people. The storyline of 2023 wasn’t “devices exist.” It was “devices are getting smarter, more automated,
and increasingly supported by clinical guidelines.”

2) CGMs Got Smaller, Faster, and More Connected

CGMs have become a cornerstone of modern diabetes management because they show glucose trends in near-real time. In practice, that means fewer “what just happened?”
moments and more “oh, I see where this is going” moments.

Dexcom G7 became available in the U.S.

Dexcom’s G7, cleared by the FDA in late 2022, launched for U.S. users in 2023. The upgrades people cared about were practical: a smaller sensor, faster warmup,
and a streamlined wear experiencechanges that can make “using the device consistently” easier, which is the part that actually changes outcomes.

Abbott’s Libre systems moved toward deeper AID integration

In March 2023, the FDA cleared certain FreeStyle Libre 2 and Libre 3 sensors for integration with automated insulin delivery systems. The big deal here is
interoperability: the diabetes tech world works best when CGMs and pumps can “talk” to each other safely and reliably.

Time in Range became more mainstreamnot just A1C

A1C remains a key measure, but CGM helped push a more nuanced view: Time in Range (how many hours per day glucose stays within a target range)
can reflect day-to-day quality of control and reduce “average looks fine, but the ride was terrifying” situations. In 2023, more clinicians and patients were
treating the CGM report like a useful mapnot a judgmental report card.

3) Medicare Expanded CGM Coverage, Which Is a Treatment Advancement (Yes, Really)

A breakthrough that sits on a shelf because no one can afford it isn’t much of a breakthrough. In 2023, Medicare broadened coverage criteria for CGM, expanding
access for insulin-treated individuals and certain people with problematic hypoglycemia even if they aren’t using insulin.

Why that matters: CGM isn’t just a convenience. For many people, it’s a safety tool that can reduce severe lows, improve treatment decisions, and support better
outcomesespecially when paired with education and clinician follow-up.

Also, this change sent a signal beyond Medicare. Coverage policies often influence broader adoption and normalize CGM as “standard of care” rather than “special gadget.”

4) The First FDA-Approved Donor Islet Cell Therapy: Lantidra

One of the most historic 2023 milestones: the FDA approved Lantidra (donislecel), the first allogeneic (donor-derived) pancreatic islet cell therapy
for certain adults with type 1 diabetes who have repeated episodes of severe hypoglycemia despite intensive management.

This is not a mass-market cure and it’s not for most people with diabetes. It’s a highly specialized therapy with strict eligibility criteria and a complex clinical pathway.
But it matters because it represents a new category of FDA-approved treatment for a population with serious riskpeople whose glucose is dangerously difficult to manage.

Big-picture significance: 2023 made “cell therapy for diabetes” feel less like science fiction and more like a regulated clinical realitystill early, still limited,
but undeniably real.

5) The “More Than Glucose” Era for Type 2 Diabetes Medications

Diabetes meds in 2023 weren’t just about lowering glucose. The conversation increasingly centered on cardiovascular risk, kidney protection,
and weight managementbecause those are major drivers of long-term health in type 2 diabetes.

GLP-1 receptor agonists and SGLT2 inhibitors stayed in the spotlight

By 2023, guidelines strongly reflected a person-centered approach: medication choices should consider comorbidities (like heart disease or chronic kidney disease),
risk of hypoglycemia, weight goals, cost/access, and patient preferencesnot only A1C.

In plain English: the “best” medication isn’t universal. It’s the one that fits your medical needs and your real life (including what your insurance actually covers).

Tirzepatide’s ripple effect on diabetes care

Tirzepatide (brand name Mounjaro for type 2 diabetes) was approved earlier, but 2023 was a year where its impact on clinical conversations became hard to ignore.
It represents a newer class of medication that targets both GIP and GLP-1 pathways and is used (with diet and exercise) to improve glycemic control in adults with type 2 diabetes.

Clinically, many patients and clinicians discussed this category of therapies not just for A1C reduction, but also for meaningful weight loss and related metabolic improvements.
(Important note: these medications can have side effectsoften gastrointestinaland require individualized risk/benefit discussions.)

6) Insulin Affordability Improved in High-Profile Ways

In 2023, insulin affordability became a front-page issue with tangible changes. Multiple manufacturers announced major list price cuts and/or expanded patient assistance
programs. These moves didn’t change insulin’s biologybut they did change whether people could actually obtain it consistently, which is the difference between “treatment”
and “wishful thinking.”

Examples from 2023 included substantial price reduction announcements from major insulin makers and broader attention to out-of-pocket caps in certain insurance contexts.
Access improvements can reduce rationing risk, prevent emergencies, and support more stable diabetes management.

7) Prevention and Earlier Intervention Kept Gaining Momentum

The most underrated diabetes treatment advancement is the one that prevents complicationsor prevents diabetes in the first place.

More focus on identifying risk earlier

Screening and risk identification (like A1C testing for diabetes and prediabetes) is basic, but 2023 continued pushing a more proactive model:
detect risk early, intervene earlier, and reduce long-term damage.

“Stage-based” thinking in type 1 diabetes influenced care conversations

While not new in 2023, the idea that type 1 diabetes can be identified in earlier stages (before symptoms) continued to shape research, screening discussions, and family decision-making.
This matters because earlier identification can support monitoring, education, and access to specialized therapies where appropriate.

8) What Changed for Patients and Clinicians Day-to-Day

The most meaningful advancements are the ones you feel on a random Tuesdaynot only in a clinical trial abstract.

Less guesswork, more pattern recognition

With CGM, many people moved from “I don’t know why that happened” to “I see the pattern: that breakfast spikes me unless I add protein,” or “I drop after soccer practice.”
That’s not a small change; it’s the difference between reacting late and adjusting earlier.

More automationplus a new skill: managing the tech

AID can reduce decision fatigue, but it also introduces device training, troubleshooting, supply management, and data review. In 2023, the diabetes community increasingly treated
“tech literacy” and “support systems” as part of treatmentnot an optional bonus.

Shared decision-making got more practical

2023 guidelines and real-world practice increasingly aligned around one truth: diabetes care works best when patients and clinicians choose treatments together.
The best plan is the one someone can actually followconsistently, safely, and without feeling like they need a PhD in endocrinology to eat a sandwich.

Frequently Asked Questions

Were these advancements only for type 1 diabetes?

No. While AID milestones are closely associated with type 1 diabetes, CGM expansion, medication strategy shifts, and affordability changes strongly affected type 2 diabetes care as well.

Did 2023 “solve” diabetes?

Nobut it improved tools, access, and specialized treatment options. The pattern is progress-by-iteration: better devices, broader coverage, smarter guidelines, and expanding therapy categories.

What’s the “biggest” advancement?

It depends on the person. For someone with severe hypoglycemia, expanded CGM coverage or specialized therapies can be life-changing.
For others, an AID system may reduce daily burden the most. For many, lower insulin costs are the biggest “real-world” breakthrough.

Real-World Experiences: Living Through the 2023 Upgrades (About )

The best way to understand 2023’s diabetes treatment advancements is to imagine how they changed ordinary days.
For many people using older tools, diabetes management used to feel like driving at night with dim headlights: you could see a little, but not enough to feel confident.
CGM made the road brighternot perfect, but clearer. Instead of a handful of fingerstick snapshots, people could see trends. That meant fewer “surprise” highs after meals,
fewer mysterious lows after activity, and more informed conversations at clinic visits.

People starting newer CGM models in 2023 often described the upgrade in unglamorous but meaningful terms: sensors that felt easier to wear, less intrusive, and simpler to insert.
Those details sound small until you remember this is something someone might use every day for years. When a device is easier to use, people are more likely to keep using itand
consistency is where the benefits compound.

Automated insulin delivery brought a different kind of relief: mental relief. Many users describe a constant background taskquietly calculating insulin needs,
correcting highs, preventing lows, and second-guessing everything. AID systems didn’t remove responsibility (people still count carbs, dose meals, and handle site changes),
but they often reduced the feeling that one mistake would spiral into a bad day. Nighttime, in particular, became less stressful for some users and caregivers because the system could
adjust insulin based on CGM trends instead of waiting for a human to wake up and notice a problem.

Clinicians saw changes too. Visits began to include more CGM report reviewsless “tell me your numbers” and more “let’s look at your patterns.”
That shifted the tone from blame to problem-solving. Instead of judging a single A1C number, teams could discuss why glucose rose at specific times or why lows happened on certain days.
For people who felt discouraged by “average” results that didn’t reflect their daily struggle, this was validating: the data showed the work they were doing.

Access improvements were a huge part of the lived experience in 2023. Expanded Medicare CGM coverage meant some people could finally use a CGM who previously couldn’t.
And insulin price announcements mattered because they reduced a terrifying calculation many families faced: “Can we afford the medicine that keeps me alive?”
When treatment becomes more affordable, people can follow safer plans, keep backups, and avoid rationingall of which directly affect outcomes.

Finally, the approval of a donor islet cell therapy (Lantidra) landed emotionally for many in the diabetes community. Even if most people would never qualify for it,
it symbolized progress: new therapeutic categories are possible, regulated, and real. For people who have watched “promising research” come and go,
2023 offered a rare moment where the headline wasn’t hypeit was an FDA approval with a defined clinical use.

Conclusion

The top diabetes treatment advancements in 2023 shared one theme: making diabetes care more doable.
Smarter automation reduced daily burden. Better CGMs improved visibility and safety. Guidelines reinforced person-centered choices that consider heart, kidneys, weight,
and hypoglycemia risk. Affordability efforts helped turn “available treatment” into “actual treatment.” And for a narrow but important group, cell therapy became a newly approved option.

Diabetes care is still complex, but 2023 moved the field forward in ways that showed up in real livesfewer emergencies, more data-driven decisions, and a little more breathing room.

The post Top Diabetes Treatment Advancements in 2023 appeared first on Best Gear Reviews.